Pharmaceutical Drugs Going off Patent in 2018

Patent expiry is one of the major factor affecting the company revenue. Often when the generic competitor of a blockbuster drugs enters the market, the sales of the blockbuster drugs has decreased significantly. For instance, the patent expiry of Pfizer’s Lipitor has resulted in about 90% decrease in the annual sales revenue of the drug. In 2016, Astra Zeneca lost patents for two major drugs, Cestor and Seroquel XR which accounted for a combined revenue of $7.34 billion annually. In 2017, Merck lost the patents for four drugs (Invanz, Vytorin, Cancidas, and Cubicin) that was estimated to value around $3.4 billion, which is 10% of their 2015 revenue.

Here are a few of the key drugs going off-patent in 2018.

Brand Manufacturer Indication
Acanya Valeant Pharmaceuticals International, Inc Skin (topical) to treat acne vulgaris
Adcirca United Therapeutics Corporation pulmonary arterial hypertension
Adavir GlaxoSmithKline Asthma and COPD
Ampyra Acorda Therapeutics Multiple Sclerosis
Apidra Sanofi Diabetes
Atripla Gilead Sciences, Inc HIV
Cialis Eli Lilly Erectile dysfunction
Epogen/Procrit Amgen and Johnson & Johnson Anemia
Fentora Cephalon, Inc Management of breakthrough pain in cancer patients
Finacea Bayer HealthCare Pharmaceuticals. Hyperpigmentation
Follistim Merck Infertility
Fortesta Endo Pharmaceuticals Hypogonadism
Levitra Bayer HealthCare Pharmaceuticals. Erectile dysfunction
Letairis Gilead Sciences, Inc Pulmonary arterial hypertension
Lotronex severe irritable bowel syndrome (IBS) Sebela Pharmaceutical
Lyrica Pfizer Nerve and muscle pain
Makena AMAG Pharmaceuticals, Inc Female Hormone Related Cancer
Namenda XR Allergan Dementia
NuvaRing Merck Contraceptive
Pradaxa Boehringer Ingelheim Pharmaceuticals, Inc. blood thinner
Promacta Novartis To treat low blood platelet counts due to chronic immune (idiopathic) thrombocytopenia (ITP)
Remodulin United Therapeutics Pulmonary arterial hypertension
Revlimid Amgen White blood cell booster
Restasis Allergan Dry Eyes
Rituxan Roche Blood cancers, rheumatoid arthritis
Sensipar Tablet Amgen Calcium Reducer
Spiriva Boehringer Ingelheim Pharmaceuticals, Inc. Chronic Obstructive Pulmonary Disease (COPD)
Staxyn GlaxoSmithKline Erectile dysfunction
Symbicort Astra Zeneca Asthma
Tekturna Noden Pharma USA Inc Blood Pressure
Tikosyn Pfizer Irregular Heartbeat
Vesicare Astellas Pharma Overactive Bladder
Xolair Roche/Novartis Allergic asthma and chronic idiopathic urticaria
Zytiga Johnson & Johnson Prostate cancer


Company wise analysis

company wise analyse

– Rikitha
Healthcare Market Research Analyst
Infoholic Research